Mizutani Y, Okada Y, Terachi T, Yoshida O
Department of Urology, Faculty of Medicine, Kyoto University, Japan.
J Urol. 1996 Mar;155(3):888-92; discussion 892-4.
Cell-mediated immunity is an important and central mechanism of host resistance to cancer. Many studies have used cultured tumor cell lines as targets for cell-mediated cytotoxicity. However, it is difficult to interpret the data generated from the cytotoxic activity against cultured tumor cell lines, since they may not represent the activity against fresh autologous tumor cells. We examined the prognostic significance of circulating antitumorigenic cytotoxic lymphocytes at operation.
Peripheral blood lymphocytes derived from 89 patients with a bladder tumor were tested at operation for cytotoxic activity against a natural killer sensitive myeloid leukemia line K562, a human bladder tumor cell line T24 and freshly isolated autologous tumor cells in a 12-hour 51chromium release assay. The levels of the cytotoxic activity were evaluated for potential prognostic significance.
The mean cytotoxic activities of peripheral blood lymphocytes against K562 cells, T24 cells and autologous tumor cells were 37.2%, 19.8% and 9.7%, respectively, using an effector-to-target cell ratio of 40:1. Based on the analysis, patients with bladder tumors were divided into 2 groups of high (greater than the mean value) and low (less than the mean value) cytotoxic activity. The magnitude of the anti-K562 or anti-T24 cytotoxic activity did not correlate with the 5-year survival rate or the postoperative disease-free period. In contrast, bladder tumor patients with high anti-autologous cytotoxic activity had higher disease-specific survival rates and a longer postoperative tumor-free interval compared to those with low activity during the 5-year follow-up. In addition, similar analysis of the data at an effector-to-target cell ratio of 20:1 revealed that patients with high anti-autologous tumor cytotoxic activity also had a higher survival rate and a longer postoperative tumor-free period than those with low activity. No statistical differences were observed in patient age and sex, as well as the size, number, histological grade and stage of bladder tumors between patients with high and low anti-autologous tumor cytotoxic activity. The anti-autologous tumor cytotoxic activity was not paralleled with either anti-K562 or anti-T24 cytotoxic activity.
These results suggest that anti-autologous tumor cytotoxic activity of peripheral blood lymphocytes might be a significant and independent prognostic indicator in patients with bladder tumors, and that the autologous tumor cell killing system might have an important role in the immune surveillance against bladder tumors.
细胞介导的免疫是宿主抵抗癌症的重要核心机制。许多研究将培养的肿瘤细胞系用作细胞介导的细胞毒性作用的靶标。然而,很难解读针对培养的肿瘤细胞系的细胞毒性活性所产生的数据,因为它们可能无法代表针对新鲜自体肿瘤细胞的活性。我们研究了手术时循环抗肿瘤细胞毒性淋巴细胞的预后意义。
对89例膀胱肿瘤患者手术时采集的外周血淋巴细胞进行检测,在12小时的51铬释放试验中检测其对自然杀伤敏感的髓系白血病细胞系K562、人膀胱肿瘤细胞系T24和新鲜分离的自体肿瘤细胞的细胞毒性活性。评估细胞毒性活性水平的潜在预后意义。
效应细胞与靶细胞比例为40:1时,外周血淋巴细胞对K562细胞、T24细胞和自体肿瘤细胞的平均细胞毒性活性分别为37.2%、19.8%和9.7%。基于该分析,膀胱肿瘤患者被分为高(大于平均值)和低(小于平均值)细胞毒性活性两组。抗K562或抗T24细胞毒性活性的大小与5年生存率或术后无病期无关。相比之下,在5年随访期间,抗自体细胞毒性活性高的膀胱肿瘤患者与活性低的患者相比,具有更高的疾病特异性生存率和更长的术后无瘤间期。此外,在效应细胞与靶细胞比例为20:1时对数据进行的类似分析表明,抗自体肿瘤细胞毒性活性高的患者也比活性低的患者具有更高的生存率和更长的术后无瘤期。抗自体肿瘤细胞毒性活性高和低的患者在年龄、性别以及膀胱肿瘤的大小、数量、组织学分级和分期方面均未观察到统计学差异。抗自体肿瘤细胞毒性活性与抗K562或抗T24细胞毒性活性均不平行。
这些结果表明,外周血淋巴细胞的抗自体肿瘤细胞毒性活性可能是膀胱肿瘤患者重要且独立的预后指标,并且自体肿瘤细胞杀伤系统可能在针对膀胱肿瘤的免疫监视中发挥重要作用。